文献速递遗传性与小管间质肾病水电解质与酸碱

CHK-336:首创新一类肝靶向小分子乳酸脱氢酶抑制剂治疗高草酸尿症的特征分析

Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment.
PubMed 文献 · J Am Soc Nephrol · 2025-04-07

原发性高草酸尿症(PH)1–3型由肝脏草酸生成增多导致。乳酸脱氢酶A催化肝草酸合成的最终步骤,是潜在治疗靶点。CHK-336是一种肝靶向小分子乳酸脱氢酶A抑制剂,在酶、细胞及体内模型中显示强效选择性抑制,在大鼠药效模型抑制13C2-乙醇酸转化为13C2-草酸,在PH1和PH2小鼠模型降低尿草酸。

要点

  • CHK-336是肝靶向小分子LDH抑制剂,可抑制肝草酸合成最终步骤。
  • 在大鼠药效模型,CHK-336剂量依赖性抑制13C2-乙醇酸转化为13C2-草酸。
  • 在PH1小鼠模型,每日一次口服CHK-336使尿草酸剂量依赖性降至正常范围。

核心结论

  • CHK-336是一种强效、肝靶向的小分子LDH抑制剂,在大鼠药效模型及PH1和PH2小鼠模型中抑制尿草酸生成。

研究设计与样本

  • 研究在酶、细胞和体内模型中鉴定并表征具有肝靶向组织分布的强效选择性LDH抑制剂。
  • 使用多种物种肝细胞(包括PH1小鼠分离肝细胞)、小鼠/大鼠/猴及大鼠药效模型、PH1和PH2小鼠模型。

主要发现

  • CHK-336在酶和肝细胞实验中显示对人LDH酶及其活性的强效选择性抑制。
  • CHK-336在小鼠、大鼠和猴中显示良好肝分布,依赖有机阴离子转运多肽的肝摄取和靶点介导药物结合。
  • 在大鼠药效模型,CHK-336剂量依赖性抑制13C2-乙醇酸转化为13C2-草酸。
  • 在PH1小鼠模型,每日一次口服CHK-336使尿草酸剂量依赖性大幅降至正常范围。
  • 在PH2小鼠模型,7天CHK-336治疗显著降低尿草酸。

临床怎么用

  • CHK-336作为肝靶向LDH抑制剂,可能用于治疗PH及其他草酸生成增多相关高草酸尿症。
  • 目前证据来自临床前模型,尚需临床研究验证疗效和安全性。

局限性

  • 研究为临床前酶、细胞和动物模型,尚未在人体中验证。
  • 原文未报告人体剂量、药代动力学、疗效或安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Primary hyperoxalurias are genetic diseases defined by elevated hepatic oxalate production and higher incidence of kidney stones. Lactate dehydrogenase A catalyzes the final and committed step in hepatic oxalate synthesis and represents a potential therapeutic target for primary hyperoxalurias. CHK-336 is a liver-targeted, small-molecule lactate dehydrogenase A inhibitor with potential to treat diseases associated with elevated oxalate production. BACKGROUND: Primary hyperoxalurias (PH) 1–3 are genetic diseases defined by elevated hepatic oxalate production and higher incidence of calcium oxalate kidney stones and potentially kidney failure. There are two approved agents available for PH1, and there are no approved therapies for PH2 or PH3. Lactate dehydrogenase A catalyzes the final step in hepatic oxalate synthesis and represents a potential therapeutic target for PH and other forms of hyperoxaluria associated with increased oxalate production. METHODS: Potent and selective lactate dehydrogenase (LDH) inhibitors with liver-targeted tissue distribution were identified and characterized in enzymatic, cellular, and in vivo models. RESULTS: We identified CHK-336, a novel oral small-molecule that demonstrates potent and selective inhibition of the human LDH enzyme and its activity in hepatocyte assays across multiple species, including hepatocytes isolated from PH1 mice. CHK-336 demonstrated a favorable liver distribution profile in mice, rats, and monkeys that was dependent on hepatic uptake by organic anion-transporting polypeptide transporters and target-mediated drug binding. In a rat pharmacodynamic model, CHK-336 inhibited conversion of 13C2-glycolate to 13C2-oxalate in a dose-dependent manner. In a PH1 mouse model, once-daily oral dosing of CHK-336 produced robust and dose-dependent reductions in urinary oxalate to the normal range. Seven days of treatment with CHK-336 also resulted in a significant reduction in urinary oxalate in a PH2 mouse model. CONCLUSIONS: In conclusion, CHK-336 is a potent, liver-targeted, small-molecule LDH inhibitor that suppressed urinary oxalate production in a rat pharmacodynamic model and mouse models of PH1 and PH2.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cox JH, Boily MO, Caron A, et al. Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment. J Am Soc Nephrol. 2025. PMID: 40193200. doi:10.1681/ASN.0000000690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。